Published Paper Details:

Abstract: Robotic technologies are emerging as promising tools in pharmaceutical drug delivery to overcome long-standing challenges in global healthcare. Robotic pills are designed to bypass enzymatic degradation and first-pass metabolism, thereby enhancing systemic bioavailability and enabling the delivery of optimal therapeutic doses without reliance on frequent injections. This approach improves patient acceptance and reduces the burden associated with needle-based administration. Oral delivery of proteins and peptides, however, is hindered by toxicity concerns, high production costs, and poor stability in the gastrointestinal environment. Issues such as injection-related discomfort and treatment non-adherence can be minimized through innovative oral delivery systems. Because luminal mucus represents a major barrier to macromolecule absorption, advanced robotic capsules have been engineered to overcome this limitation. One such system, the RoboCap, is an ingestible robotic capsule designed to enhance drug mixing, clear the mucus layer, and deposit drug directly onto the intestinal surface to improve absorption. These innovations demonstrate the potential of robotic pills to provide a safe, effective, and patient-friendly alternative to parenteral administration of bio therapeutics.